Financial Pacific - U.S. Broker and Universal Banks (third party)

UBS Investment Research

Morning Expresso - United States

Tuesday 16 August 2011

Global Equity Research

Americas

Equity Strategy

Market Comment

16 August 2011

www.ubs.com/investmentresearch

U.S. Equity Product Management

212-713-2400

Morning Expresso

This report has been prepared by UBS Securities LLC ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 18. UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

ab

Morning Expresso - United States 16 August 2011

UBS 2

Morning Meeting Agenda Estée Lauder Rating: Buy Target: US$118.00 Price: US$100.85 RIC: EL.N Prior: Unchanged Prior: Unchanged Mkt Cap: US$20.2bn BBG: EL US

Cosmetics Analyst: Nik Modi Tel: +1-212-713 2204

Beyond The Numbers: Reiterate Buy A Pattern Forming...Why Take Numbers Down to Take Them Up Again? As we indicated in our “First Read” earlier today, Estée management has

a history of providing extremely conservative initial fiscal year guidance (the company has managed to beat revenue, gross and operating margin targets as well as EPS by an average of 50% since 2009). Over the past 2 years, consensus estimates for the following year have gone down post June Q results only to rise dramatically a few quarters later (see charts in body). While consensus may come down due to guidance of $4.00-$4.20, we estimate Estee can deliver FY12 EPS of $4.40.

Did You Miss the EL Run…Sell Off Creates Entry Point Looking back to past 4Q reports, the stock has underperformed the market by close to 300 bps (usually because of conservative guidance). Investors who took advantage of these one day sell offs, experienced significant outperformance (19%/27% outperformance over 180/360 days). We continue to believe the stock sell off today was due to FY12 EPS guidance, which we believe is conservative.

What is Long Term EPS Power at Estee Lauder? Driven by accelerated category growth, share gains, white space expansion, positive price/mix, operating leverage and incremental cost savings, we estimate 13-14% EPS growth through 2015. We expect the company to be the next “10 in 10” story. That is, the company would be able to deliver high quality 10% EPS growth every year for the next 10 years.

Valuation: $118 Price Target Derived via DCF Our target implies 24x our CY12 EPS of $4.83. Notes:

Source: The content presented above reflects a front page summary of UBS Research content, UBS estimates based on a share price of US$100.85 on 12 Aug 2011 19:39 EDT

US Brokers and Universal Banks

Diversified Financial Analyst: William Tanona, CFA Tel: +1-212-713 2325

July Master Trust: early stage delinquencies begin to stabilize Credit card charge-offs should start to show signs of normalizing July master trust filings show stabilizing early stage delinquencies, which means

improvements in charge-offs should begin to moderate in a few quarters. On average, 30-89 day delinquencies were stable, while 90+ day delinquencies dropped 9 bps m/m. Default rates fell m/m for JPMorgan and ticked up modestly for BofA and Citigroup (up 17 bps for each) after falling over 100 bps last month.

No change to our outlook for credit card losses Given overall credit trends in credit card master trust data, we remain comfortable with our quarterly loss estimates for our coverage universe (5.15% for JPM, 6.59% for BAC and 9.10% for Citi).

Delinquency trends indicate NCO improvements should start to moderate Half of the master trust filings we analyze showed a modest uptick in 30-59 day delinquencies. While this data can be noisy, moderating improvements in early stage delinquencies imply the pace of credit improvements should begin to slow.

Sector attractive, but a long-term view is required While we continue to believe the sector has compelling upside potential over a two to three year time period, the near-term could remain extremely volatile given global macro stresses and uncertain economic growth. The group trades at 0.8x TBV, which we view as attractive given the group’s potential to generate low teens ROTE in a more normalized environment.

Notes:

Source: The content presented above reflects a front page summary of UBS Research content, UBS commentary as at 15 August 2011

UBS Global I/O®:IT Hardware

Technology Analyst: Maynard J. Um Tel: +1-212-713 3372

Some Signs of Life in US Back to School Recent retail checks indicate some increased PC sales activity Our recent checks suggest that the Back-To-School PC demand began to show

better relative signs of life in late July & into August. While still too early to call a positive turn, the checks are at least encouraging relative to prior data points & could result in some positive news for once if the trends are more broad-based.

Non-iPad Tablet Sell-through Still Appears to Be Lagging Non-iPad tablet sales appear to continue to lag based on our checks. Perhaps as evidence of this, a number of vendors have reduced price – HP Touchpad & ViewSonic G-Tablet dropped by $100, Acer Iconia Tab A500 by $50 at Best Buy & Wal-Mart, & the Vizio 8 inch tablet by $50 at Wal-Mart. Asus Transformer & Toshiba Thrive appear most popular of non-iPads (though iPad still dominates).

SKU count/avg ASP increase though largely due to higher DRAM configs The number of SKUs held by retailers generally increased month over month, though largely due to higher DRAM configurations of same models (4GB & 6GB). However, on a like-for-like PC basis, ASPs have generally been flat to down $200 into the August Back-to-School push.

Most & Least Preferreds Across the PC Hardware companies, Apple, Dell & Lenovo are our most preferreds while Acer and Compal Electronics are our least preferreds given their respective end market exposures and momentum. While a further deceleration in the macro-economy would have impacts to transaction-based hardware companies, we maintain our view of enterprise & emerging markets over developed consumer.

Notes:


http://research.ibb.ubs.com/doc/200266822?doc=200266822




UBS 3

U.S. Software

Software Analyst: Brent Thill Tel: +1-415-352 4694

2012 Recession? We’ve Got You Covered Shelter from the Storm To help us handicap the best performing software stocks should the economy enter into a recession we screened our

software coverage universe based on 4 criteria; 1) stocks that outperformed in 2008-09, 2) a recession scenario analysis on 2012E EPS, 3) exposure to Europe and public sector, and 4) current vs. trough valuations.

Software #1 Tech Sub-Sector in 2008-09 Recession Software stocks are likely to outperform other areas of technology in a potential recession similar to 2008-09. Compared to the rest of technology, software companies tend to be more resilient with revenue and profit less cyclical due to higher levels of recurring revenue in the form of maintenance or subscription-based business models.

Earnings and PT Scenario Analysis We examined the 2012E revenue, earnings and PT sensitivities of our coverage universe under mild and severe recession scenarios representing 2 different magnitudes of deterioration in the economic climate.

Top Recession Picks – Assumes Recession on Par with 2008-09 Our top 3 ‘most preferred’ severe recession picks are ORCL, CHKP and INTU, with heavier mixes of recurring revenues, higher priority spend categories (e.g., security), and relatively better fundamentals in the last recession. Our top 3 ‘least preferred’ severe recession picks are ADSK, ADBE and CTXS, with a lower mix of recurring revenues, companies more reliant on better environments to sell products, coupled with some valuation concerns.

Notes: Source: The content presented above reflects a front page summary of UBS Research content, UBS commentary as at 15 August 2011

Motorola Mobility Rating: Neutral Target: US$40.00 Price: US$38.13 RIC: MMI.N Prior: Buy Prior: US$31.00 Mkt Cap: US$11.2bn BBG: MMI US

Diversified Technology Services Analyst: Amitabh Passi Tel: +1-415-352 5537

Downgrading MMI to Neutral Downgrade to Neutral on Google Takeout Offer We downgrade MMI to Neutral from Buy following the $40/share, all-cash, take out offer from

Google which we consider fair. As we had previously written, our $31 price target, based on a sum-of-the parts analysis, gave no credit to the $8/share in DTAs MMI has. Ex-cash/DTAs the business is being valued at 0.5x TTM sales or 0.4x 2012 sales @ $40/share. The deal also seems fair to CEO, Dr. Sanjay Jha, who has ~5.2m options and 0.9m RSUs outstanding (~4.6m options at strike price of $35.37), and should be satisfactory to activist investor Carl Icahn.

Many Questions Remain Unanswered – More from Google’s perspective We believe many questions remain unanswered on the longer-term implications of this deal, especially from Google’s perspective, and include whether MMI’s tax-free spin-off nature would be affected by the deal; how cross-license agreements will be maintained under change of control; impact to other Android OEM partners; Google’s longer-term HW aspirations for both mobile devices and video infra. (does Google move to an integrated device model?). We don’t anticipate any major regulatory roadblocks to prevent this deal from going through.

Deal Bids Up Shares of Others Handset Players; Question Size of Moves On the back of this deal, shares of other handset makers such as Nokia and RIMM have reacted favourably. We think the scarcity premium diminishes with each IP-related deal and remain sceptical of a take out of RIMM at current levels.

Valuation: Downgrade to Neutral; Price Target to $40 PT based on Google’s takeout offer price for MMI. Notes:

Source: The content presented above reflects a front page summary of UBS Research content, UBS estimates based on a share price of US$38.13 on 15 Aug 2011 17:42 EDT UBS Global I/O®: Telecom Equipment

Technology Analyst: Gareth Jenkins Tel: +44-20-7567 3950

Implications of Google’s acquisition of MMI Input: Google to acquire MMI for $40/share, a 63% premium to last close Google announced that it will acquire MMI for $40/share (63% premium)

or total price of $12.5bn (EV of c$9.5bn), which translates to 0.6x 2012E EV/sales and 14x EV/EBIT. The deal is expected to close by end-2011 or early 2012.

Output: risks for other Android OEMs? Unlikely as Google needs scale While MMI will be run as a separate business and Android will remain open, we believe this does raise risks of conflict of interest as well as Google competing head on with other Android OEMs. Having said that, Google needs scale and as such should be largely neutral for other Android OEMs. Irrespective, Samsung, HTC may look to de-risk their OS strategy by emphasizing more on WP7, which will be positive for Microsoft, but will likely increase competition for Nokia.

Output: Does Microsoft feel compelled to own hardware? We believe this will again raise questions of a handset acquisition by MSFT given integrated hardware-software business models of Apple and now Google. We believe GOOG’s move is motivated more by IP rather than an integrated model and for MSFT we believe it is likely to continue to focus on its software strategy and wait and watch on the success of WP7 before any strategic move.

Output: highlights value of IP in the industry The value of IP comes to the fore again and we believe will lend valuation support to NOK, ERIC, ALU. In handsets our preference is for AAPL, QCOM, SEC, Spirent; least preferred are Gemalto, MediaTek, LGE, and Silitech. We also have Buy ratings on GOOG, MSFT, and downgrade MMI to Neutral from Buy on the back of this deal.

Notes: Source: The content presented above reflects a front page summary of UBS Research content, UBS commentary as at 15 August 2011





UBS 4

Google Inc. Rating: Buy Target: US$800.00 Price: US$557.23 RIC: GOOG.O Prior: Unchanged Prior: Unchanged Mkt Cap: US$178bn BBG: GOOG US

Internet Services Analyst: Brian Pitz Tel: +1-212-713 9310

Reiterate Buy: Well Positioned for Growth We reiterate our Buy on UBS Key Call GOOG as the core search business remains intact and adjacent / emerging businesses like mobile, display

advertising, and social are accelerating. We believe the stock is cheap as investors remain concerned about perceived frivolous spending, the FTC investigation, and recent management changes. But we feel these concerns are overblown given GOOG’s positioning in big, rapidly growing markets.

Core Search Intact as Emerging Businesses Accelerate Google remains the leader in global search as CPC growth and paid click growth accelerate. And the company is focusing investment in key multi-billion dollar opportunities: 1) Android has ~40% market share and GOOG sees ~2.7B AdMob ad requests daily, up 3.5x Y/Y; 2) Display is on a ~$3.5B run rate; and 3) Google+ has 25MM users in its first month; the social platform could improve ad targeting as GOOG benefits from the social graph.

Investment Thesis Outlined in Slide / Comment Format To highlight our investment thesis, we include easily digestible slides and comments starting on page 2. Also note, we believe the pending MMI acquisition is a positive for Google and Android. Please see today’s companion note entitled “Google to Acquire Motorola Mobility” for details on the $12.5B acquisition.

Valuation Represents Attractive Entry Point At ~10x 2012 Op P/E (ex-cash) we view this as a trough valuation representing an attractive entry point. Our $800 PT is based on a DCF (12% WACC, 3.5% LTGR).

Notes: Source: The content presented above reflects a front page summary of UBS Research content, UBS estimates based on a share price of US$557.23 on 15 Aug 2011 18:42 BST



UBS 5

MACRO AND STRATEGY RESEARCH US Daily Economic Comment

Economist: Maury N. Harris Tel: +1-212-713 2472

Better SLOOS, flat HMI, NY mfg weakens Preview: IP +1.0%est. Steady single-family housing activity. (1) Motor vehicles, utilities, and mining probably pushed industrial and manufacturing

production to a solid rise in July. We forecast industrial production +1.0% (cons 0.5% after 0.2%) and manufacturing +0.6%, but manuf. ex autos up a softer 0.2%.

(2) The ICSC store sales measure softened in the first week of August. The Redbook index picked up. Despite slipping prices, sales indexes have shown some net re-acceleration recently (see chart on page 4).

(3) After a surge in multi-family starts in June, we forecast a partial reversal in July, with single-family starts little changed. Permits likely followed a similar pattern, albeit with a smaller swing in multi-family. (Starts UBSe 595k, cons 600k, after 629k.)

(4) Falling natural gas and nonenergy petroleum prices probably weighed on import prices in July (UBSe 0.0%, cons -0.1%, after -0.5%). Review: Empire -7.7 after -3.8. Improved lending. HMI unchanged at 15. (1) The S&P 500 rose 2.2% on Monday and has fully reversed the

weakening of last week. Even so, it remains down 9.1% from the July average. Notes:


US Economic Comment

Economist: Maury N. Harris Tel: +1-212-713 2472

Banks eased standards more broadly in Jul Broader easing in July than in April, and stronger loan demand In the Fed's senior loan officer opinion survey for July, banks reported easing

standards on all types of loans. For almost all categories of loans, the net percentage of banks easing lending standards was larger at the start of Q3 than it had been at the start of Q2. For example, 21.8% of banks on net reported easing standards for large business C&I loans, up from 16.4% the prior quarter. Business lenders cited "aggressive competition" as the reason for easing.

There was some net easing of residential mortgage standards, commercial real estate standards, C&I standards, and nonmortgage consumer loans standards. Although a smaller net percentage of banks eased standards for small business loans (7.8% vs 13.5%) and for consumer credit cards (9.3% versus 20.5%) than had in the prior quarter, these were relatively small steps backward within a broader expansion of bank credit easing.

Demand for loans also strengthened, with the exception of residential mortgages. Also slightly soft—demand by small businesses was fairly restrained. Broader easing is more supportive of Q3 growth and hiring The net easing in lending standards and strengthening in loan demand suggests

support for spending at the start of Q3. The survey ran from July 12 to 26—fairly recent although it missed the grand finale of the Federal debt negotiations.

Notes:


http://research.ibb.ubs.com/servlet/SrchDoc/421309.pdf?doc=421309&f=aug11/xrm44860.pdf

http://research.ibb.ubs.com/servlet/SrchDoc/421305.pdf?doc=421305&f=aug11/xrm44857.pdf


UBS 6

COMMUNICATION Telecommunications & Pay TV

Broadcasting Analyst: John C. Hodulik, CFA Tel: +1-212-713 4226

Broadband makes up for weakening video Video losses doubled vs. a year ago We estimate the industry’s video losses were 436K in 2Q, more than twice the 204K lost a year ago. Cable and

satellite providers blamed the economy and increased competition for the weaker than expected results. Telcos continued to improve penetration of homes passed (VZ at 30%, AT&T at 16%), capturing a total of 7.3% market share vs. 5.6% a year ago. Satellite providers gained 40 bps of share, reaching 33.5%, while cable’s share was 59.3%, down 200 bps yoy.

Video ARPU still growing, but at a slower rate—OTT to blame? We believe the lackluster housing market continues to be the main reason for the weakness in video adds. While cord-cutting is likely impacting results at the margin, we believe the impact of over-the-top is more prevalent in ARPU trends. Cable MSOs’ video ARPU growth decelerated to 3.9% from 4.6% in 1Q, resulting in just 0.7% video revenue growth, half of the 1Q rate. We estimate total industry video revenues grew 5.2% yoy, down from 5.7% in 1Q and 6.5% a year ago.

Cable leads in broadband; Data ARPU growth accelerates Broadband subs grew 6.3% yoy in 2Q, in-line with the last four quarters. Cable continued to take a majority of the flow share, capturing 84% in 2Q vs. 66% in 1Q and over 100% a year ago. We expect this trend to continue with cable garnering 75% of flow share in 2012. Cable is also benefiting from the improved mix of higher-speed subs, boosting ARPU growth to 2.5% from 1.9% in 1Q. Cable VoIP adds slowed to 307K from 407K a year ago. This helped improve the annual declines in telco voice lines to 9.1% in 2Q from 9.4% in 1Q and 9.8% a year ago.

Notes:




UBS 7

CONSUMER Lowe's Rating: Buy Target: US$25.00 Price: US$19.68 RIC: LOW.N Prior: Unchanged Prior: US$26.00 Mkt Cap: US$25.9bn BBG: LOW US

Retailers, Broadline Analyst: Michael Lasser Tel: +1-212-713 2440

Long-term gain, short-term pain? LOW 2Q was better than feared & provided more fodder for the debate Despite a difficult sales result (including a -0.3% comp decline vs. our flat

est and the consensus est of 1.2%), Lowe’s was able to achieve a decent profitability outcome for the quarter with EPS of $0.68 (ex. charges), which was ahead of our (and the consensus) estimate of $0.66.

Lowe’s is maintaining its more aggressive stance to close the gap with HD As part of the strategy, LOW will expand its list of benchmark items that it prices competitively. While this is likely to cause some incremental gross margin pressure in the near term, the company expects that it will drive traffic gains and greater expense leverage over the long term. We think the jury is still out on the cost-benefit analysis, but the market does not appear to be ascribing a high probability of success based on the discounted valuation vs. HD.

Several near-term factors should support the stock We think there are several appealing factors for LOW’s near-term investment case: The company has set a lower bar for 2H’11 by guiding to flat comps (note that comps are running positive QTD). Also, we expect LOW should see less of a drag from soft appliance trends. This caused a ~50 bps comp drag in 2Q’11. Lastly, we believe Lowe’s should continue to generate strong expense leverage (2Q’11 op margin expanded 34 bps).

Valuation: LOW trading at a 9% FCF yield & less than 6x ‘11E EBITDA In our view, LOW’s attractive valuation should provide some potential downside support even as its gross margin outlook is more uncertain. Our $25 target is based on a blend of a DCF and multiple analysis (equates to 14x our CY’12 EPS est of $1.76).

Notes:


http://research.ibb.ubs.com/doc/


UBS 8

ENERGY Transocean Rating: Buy Target: US$72.00 Price: US$57.26 RIC: RIG.N Prior: Unchanged Prior: Unchanged Mkt Cap: US$18.3bn BBG: RIG US

Oil Drilling, Equipment & Services Analyst: Angie Sedita Tel: +1-212-713 3587

Acquiring Aker Drilling (4 Ultra-deep rigs) Total offer price $3.13 bil (incl cash + acq’d net debt + construction capex) RIG will acquire Aker Drilling for a total consideration of $3.13 bil

($1.43 bil in cash + $800 mil assumed Aker debt + $900 mil in remaining CAPEX to complete the construction of the two newbuild drillships). On a valuation basis RIG paid the construction costs of the rigs ($3.1 bil construction costs); however, on a NAV basis we estimate a slight premium of 10%-12% to NAV (still looks reasonable).

Aker brings 4 new high spec ultra-deepwater rigs + 2 options Aker operates two harsh environment, ultra-deepwater, 6th gen semi-submersible rigs on long-term contract in Norway (adds $1 bil in backlog). Aker also has two ultra-deepwater drillships under construction at the Daewoo Shipyard in Korea, expected to be delivered late-2013. The two drillships will cost $600 mil to build and are both uncontracted. The two harsh-environment semis were constructed for $950 mil each. Aker also has two attractively priced drillship options at $600 mil with 25% due at signing and the remainder at completion, options expire Oct 11.

View deal as modest positive, adds high quality rigs to fleet We view the deal as a modest positive given: 1) a seemingly reasonable valuation based on construction costs; 2) the high specification nature of the rig fleet; 2) greater exposure to attractive and steady Norway market; 3) the strong free cash flow position of RIG; 4) Transocean’s unwillingness to build without contract and thus a method to expand the fleet; 5) the well priced options for two more ultra-deepwater rigs.

Valuation: Maintain Buy Rating – RIG trading at 12% disc to peers on ‘12E Our $72 price target is based on a 6.6x 2012E EV/EBITDA multiple. Notes:


US Electric Utilities & IPPs

Utilities Analyst: Julien Dumoulin-Smith Tel: +1-212-713 9848

Examining the Possibilities in NJ NJ BPU: Settlement discussions underway, but we remain doubtful Following the FERC’s conference on Minimum Offer Price Rules (MOPR), the

NJ BPU and PJM have engaged in settlement discussions. Parties remain fixated on a solution for long term procurement under the RPM capacity auction (BPU suggests 10-yr contracts are a min.); an extended New Entry (NEPA) mechanism to 7-9 years remains a viable compromise in our view, allowing for new and incumbent generators to lock in capacity prices (election of this option must be chosen ahead of a given auction, likely limiting use by existing generators). That said, NJ’s insistence on nearer term solutions outside of RPM likely prevent an amenable resolution; unconvincingly, the BPU suggested in meetings that reliability was threatened as PJM’s reserve margin and demand projections were too low.

LCAPP #2: Coming soon, and with a twist that could improve its chances We believe a second (~1GW) LCAPP solicitation is likely forthcoming. While terms are ambiguous, we anticipate the state to subsidize capacity through economic development funds, tax abatement, and municipal financing arrangements among other “options” being considered by the BPU, designed specifically to allow bidders to apply for an exemption under the MOPR. Enabling legislation is needed and would likely be approved (albeit with slimmer support from Democrats). While LCAPP #2 would supplement the original procurement, we believe the winning bids under the original LCAPP SOCA agreements would never be developed, allowing for these assets to be re-procured under the latest solicitation. As a consequence, we believe it conceivable (although certainly not definite) new capacity under LCAPP could clear the RPM market in MAAC at current levels.

Notes:



http://research.ibb.ubs.com/servlet/SrchDoc/200266835.pdf?doc=200266835&f=aug11/uea13789.pdf


UBS 9

HEALTHCARE Pfizer Rating: Buy Target: US$23.00 Price: US$18.21 RIC: PFE.N Prior: Unchanged Prior: Unchanged Mkt Cap: US$147bn BBG: PFE US

Pharmaceuticals Analyst: Marc Goodman Tel: +1-212-713 1342

Pfizer Wins Viagra; Bumping Estimates What’s new? District Court rules in Pfizer’s favor against Teva Pfizer initially sued Teva for patent infringement on the ‘012 patent in March 2010.

On Friday, the US District Court in Virginia ruled that Teva did not show the ‘012 patent to be invalid for obviousness nor for double-patenting, and that Pfizer did not commit inequitable conduct. Thus, the patent is valid and enforceable until October 2019 (excluding pediatric exclusivity).

Our takeaway: Upside to Pfizer, we had been expecting generics The fact that Pfizer will retain Viagra until 2019 is a substantial positive and counter to our expectations that Teva would enter sooner. We have updated our model to reflect patent protection through 2019, which on its own represents an upside in EPS of ~$0.08-0.12 per year through 2016. For now, we assume 50% of this upside will flow to the bottom line, with the rest being reinvested in spending, resulting in an increase of ~$0.04-0.06 per year in our numbers.

Thoughts on the stock: Further upside in an already undervalued stock We believe PFE is undervalued and the Viagra win is substantial upside to our existing numbers. We look for Apixaban data at ESC and Tofacitinib data at ACR to be the major catalysts for the remainder of the year.

Valuation: We maintain our Buy rating and $23 PT based on our DCF The implied P/E multiple from our DCF is 10x our 2012E EPS of $2.30. Notes:


US Medical Devices

Advanced Medical Devices Analyst: Rajeev Jashnani, CFA Tel: +1-212-713 9127

JNJ & ABT : weekly Rx for wk ending 8/5 JNJ: Zytiga, Stelara & novel anti-coagulant updates Zytiga: absolute TRx / NRx were 856 / 422 (averages over the prior 4-wks: 762/ 404). Wkly Rx

volume has been relatively steady over the past few wks; we expect improvement after summer months. Implied run rate currently stands at $235M. Stelara: TRx up 86%. Among sub-cu products, mkt share in derm stands at 19.1% (+90 bps relative to 4-wk average; +440 bps YTD). Xarelto: posted TRx of 406, 231 & 96 over the past 3 wks. Implied annual run rate is immaterial at this level (<$5M). Product was approved for deep vein thrombosis in pts undergoing knee or hip replacement surgery on 7/1; key upcoming event is FDA a-fib panel on 9/8. Notably, in the novel anti-coagulant space, Pradaxa penetration is still hovering in 7-8% range; we expected better uptake.

ABT: Humira growth solid; Niaspan declines may be manageable Humira: YOY TRx growth 11% (12-wk moving average: 12%) relative to sub-cu market growth of 8% (12-wk moving average: 9%). We model 3Q11 sales of $855M; current brand performance suggests incremental sales upside of $30M (~$0.01-$0.02 benefit to EPS). Tricor franchise: TRx volumes remain weak at -15% (12-wk moving average: -15%). That said, ABT has managed revs effectively w/ sales +1% in 2Q11 despite -14% in TRx, which we attribute to pricing (+14% cumulatively) and lower performance rebates. Niaspan: YOY TRx declines seem to have moderated at -10%. Despite soft volumes, we think ABT can manage revs similar to Tricor.

Notes:


U.S. Pharmaceuticals

Pharmaceuticals Analyst: Marc Goodman Tel: +1-212-713 1342

Weekly Rx Tracker Issuing weekly Rx tracker for week ending August 05, 2011 This report tracks the weekly Rx trends and the required growth rates to meet our

sales forecasts for upcoming quarters for key new launches and switches. Our takeaways for this week for specialty pharmaceuticals For AGN, Latisse (-11% Y/Y) declined as did CEPH’s Amrix (-85% Y/Y). FRX’s Bystolic

(+34% Y/Y) and Savella (+20% Y/Y) grew while PFE’s Embeda (-100% Y/Y) continued to fall strongly (due to recalls on March 15). WPI’s Gelnique (+1% Y/Y) & Rapaflo (+95%) continued their growth. Lastly, WCRX’s Actonel (-33% Y/Y) and Asacol (-12% Y/Y) continued to decline.

Our takeaways for this week for large cap pharmaceuticals For MRK, Dulera (+6% sequential) and Saphris (+102% Y/Y) grew. BMY’s Orencia (-24% Y/Y) declined. LLY’s Effient grew (+126% Y/Y). For NVO, Victoza (+104% Y/Y) increased. Lastly, PFE’s Chantix (-16% Y/Y), Lipitor (-4% Y/Y) and Lyrica (-1% Y/Y) continued to decline as expected.

Our takeaways for key switches we are watching For Asacol-Asacol HD, Asacol HD’s share increased to 25.1% of NRxs from 25.4% last week while for Provigil/Nuvigil, Nuvigil’s share decreased to 47.9% of NRxs vs 48.5% last week. In the DPP-IV market, NRxs grew 25% Y/Y. Onglyza/Kombiglyze XR/Tradjenta gained modest share with Januvia/Janumet holding at 82.6% share vs 82.7% last week. Xifaxan’s NRxs increased 0.4% Y/Y and the switch trend continued with 550mg now at 73.0% of NRxs vs 72.1% last week. Additionally, generic Concerta had 78.9% of NRxs (vs 77.1% last week).

Notes:






UBS 10

INDUSTRIALS Boeing Rating: Neutral Target: US$73.00 Price: US$61.68 RIC: BA.N Prior: Unchanged Prior: Unchanged Mkt Cap: US$45.7bn BBG: BA US

Aerospace Analyst: David E. Strauss Tel: +1-212-713 6185

Tracking Dreamlifter Activity Watching flights into Paine Field in Everett We are tracking movements of Boeing’s modified 747 “Dreamlifter” fleet to gauge the progress of 787

production. Specifically, we are monitoring Dreamlifter flights into Snohomish County Paine Field Airport, adjacent to 787 production, to gauge the pace of shipments from the structural suppliers. 787 structural components are delivered via the Dreamlifter fleet to Boeing in Everett, WA for final assembly. We are now also monitoring Dreamlifter deliveries into Charleston associated with the opening of the second production line.

Flights into Everett resume We have tracked five Dreamlifter arrivals in total into Everett so far in August. This is well above the prior month’s pace as Boeing has resumed component deliveries into Everett following a roughly three-week pause, although still lower than levels seen in early 2010. We have also tracked one flight into Charleston for the second production line so far in August.

Need to see increase in Dreamlifter activity We think the still slow pace of structural component deliveries reflects supply-chain problems and rework necessary on early aircraft. Dreamlifter activity had been relatively consistent at 15-20 monthly arrivals into Everett since the Machinists strike in late 2008. However, activity has been slow since mid-2010 with Boeing now having halted component deliveries into Everett five times.

Valuation: Neutral Rating, $73 price target Our $73 PT reflects our DCF analysis (10% WACC, 3% terminal growth rate). Notes:


Danaher Rating: Buy Target: US$60.00 Price: US$44.72 RIC: DHR.N Prior: Unchanged Prior: Unchanged Mkt Cap: US$28.9bn BBG: DHR US

Industrial, Diversified Analyst: Jason Feldman Tel: +1-212-713 4309

Agilent’s F3Q results consistent with outlook for DHR’s Test & Measurement unit Agilent’s F3Q results (July) relevant for DHR’s Test & Measurement unit We believe Agilent’s Electronic Measurement Group (EMG) is a good

comp for DHR’s Tektronix business (Tek is roughly half of DHR’s T&M segment, which is ~1/5 of DHR sales pro forma for BEC). Their product mix is similar, including key products like oscilloscopes and other electronic test & measurement equipment.

Agilent expects +11% YoY sales growth in F4Q ending in October At the mid-point, Agilent’s F4Q (October-end) sales guidance implies +11% YoY growth. Mgmt’s overall outlook was relatively positive; while softer vs last quarter, unless gov’t spending is materially cut, underlying demand is “expected to be roughly the same.” In F3Q, Agilent reported organic revenue growth of 19% YoY, and +14% YoY ex-FX (down slightly vs 21% YoY in F2Q). EMG revenues grew 24% YoY on an organic basis in F3Q, down slightly vs 26% in F2Q. Europe was weak (unsurprisingly) and declined 1% organically in F3Q vs +19% YoY in F2Q.

Agilent’s results/commentary consistent with DHR’s guidance In DHR’s 2Q (June-end vs. July-end for Agilent) the T&M segment had organic sales growth of ~13.5% (+9.5% core, excluding +4% from FX). We believe Agilent’s results are consistent with overall expectations for T&M, as well as DHR’s formal FY2011 guidance (+6-8% organic growth across DHR ex-FX).

Valuation: Buy rating and $60 price target PT reflects a ~45-50% premium to the market multiple on our 2011 EPS estimate. Notes:


USDA Crop Progress Report

Heavy Machinery Analyst: Henry Kirn, CFA Tel: +1-212-713 4895

Corn crop condition still slightly below normal Corn crop steady at 60% in “good” or “excellent” condition Today, USDA reported 60% of the corn crop is in “good” or “excellent” condition, in

line with last week’s 60%, but below last year’s 69%. See page 2 for a chart depicting this year’s corn crop condition compared with that of prior years. Corn, soybeans and wheat futures prices rose last week Corn prices increased 5% last week and are 74% above year-ago levels, while soybean

prices rose 3% last week and are up 30% YoY. Wheat prices were 9% higher over the past week and are up 7% YoY. We see solid farm profitability as catalyst for farm equipment demand We note corn, soybean and wheat prices remain well above historical

averages. USDA forecasts farm cash net income to increase 8% YoY in 2011, and we see the strength in farm profitability as likely to drive strong farm equipment demand through 2012.

We continue to favor Key Call Buy-rated DE for exposure to the NA ag cycle We remain bullish on the farm equipment cycle, as our channel checks indicate both improving demand and pricing. DE remains a UBS Key Call and our preferred way to play the farm equipment cycle as we continue to see beats over the next few quarters as a catalyst for outperformance. Additionally, we maintain our Buy ratings on AGCO and CNH as we expect recent strength in farm commodity prices to be a likely positive catalyst for shares.

Notes:






UBS 11

TECHNOLOGY

HiSoft Technology Rating: Buy Target: US$21.00 Price: US$11.52 RIC: HSFT.O Prior: Unchanged Prior: Unchanged Mkt Cap: US$0.36bn BBG: HSFT US

Diversified Technology Services Analyst: Arvind Ramnani Tel: +1-212-713 3517

Solid June quarter results; guidance raised Strong June quarter results As we had anticipated in our preview note on 8/5, HSFT posted strong F2Q results. F2Q revs. of $50.9M (+46.6% y/y

and 14.8% q/q) was well ahead of UBSe/Street est. of $47.2M, and adj. EPS of $0.18 was in-line with our ests & 0.01 ahead of St. ests. Employee headcount increased by 464, from 5,946 in F1Q to 6,410 in F2Q. Revenue growth was driven by quicker than expected recovery of its Japanese business (consistent with our checks) & strong growth from its domestic China business (+272% y/y). 2Q adj margins of 11.2% was 20bps ahead of our estimates.

Impressive guidance raise F11 revenue guidance was upped to “at least” $212M (+44.6% y/y) from “at least” $194.5M (+32.7%) well above UBSe/St’s estimates of $200.2M/$197.9M. EPS guidance was upped to $0.80-$0.84 from $0.76-$0.80, above UBSe/St.’s estimates of $0.79/$0.78. F3Q revenue guidance of $56M-$57M is well above UBSe/St’s $51.3M/$50.7M and EPS guidance of $0.22-$0.23 is in-line with UBSe of $0.22 and slightly above Street estimates of $0.21.

Key questions for 6:00pm ET call today (Dial-in 800-860-2442) 1) Impact of macro headwinds on demand trends; 2) How much of a buffer (in terms of a potential double-dip recession) does 2011 guidance have; 3) Spending pattern among top-10 clients; 4) Update on Japan business.

Valuation: Buy rating and $21 PT (based on 18x C12 P/E and DCF) We will review our model after the 6pm ET call. Notes:




UBS 12

UBS Key Calls - US Live Key Call Portfolio

Stock Name RIC Rating Price Target Date of call Current Price Analyst Apple Inc. AAPL.O Buy US$510 2-Jun-11 US$383.41 Maynard Um

Baker Hughes Inc. BHI.N Buy US$102 7-Jun-11 US$64.57 Angie Sedita

Cardinal Health, Inc. CAH.N Buy US$51 18-Jan-11 US$41.6 Steven Valiquette

Celgene Corporation CELG.O Buy US$71 9-Dec-10 US$55.74 Matthew Roden, PhD

Citigroup Inc C.N Buy US$56 3-May-11 US$31.27 William Tanona, CFA

CONSOL Energy, Inc. CNX.N Buy US$74 4-Aug-11 US$42.37 Shneur Gershuni, CFA

Deere & Co. DE.N Buy US$115 18-Jan-11 US$76.5 Henry Kirn, CFA

Dow Chemical DOW.N Buy US$46.5 21-Mar-11 US$30.08 Andrew Cash

Ford Motor Co. F.N Buy US$22 10-Jan-11 US$11.35 Colin Langan, CFA

General Electric Co. GE.N Buy US$23 10-Jan-11 US$16.39 Jason Feldman

Google Inc. GOOG.O Buy US$800 10-May-10 US$557.23 Brian Pitz

Joy Global Inc. JOYG.O Buy US$112 28-Feb-11 US$81.98 Henry Kirn, CFA

McDonalds Corp. MCD.N Buy US$97 9-Feb-11 US$86.82 David Palmer

Prudential Financial Inc. PRU.N Buy US$77 19-Apr-10 US$52.5 Andrew Kligerman

Qualcomm Inc. QCOM.O Buy US$70 26-Apr-11 US$51.26 Parag Agarwal

SanDisk Corp. SNDK.O Buy US$62 21-Mar-11 US$38.2 Uche Orji

Source: Reuters, UBS. Prices as at market close on August 15, 2011.


UBS 13

Rating & PT Changes Key Rating and Price Target Changes: US

Company Name Directional Indicator/Rationale Reuters Code Current Share Price

New Rating New PT Prior

Rating Prior PT

Lowe's Companies, Inc. Reiterate Buy, lower PT LOW.N US$19.68 Buy US$25 Buy US$26

Motorola Mobility Holding Inc Downgrade to Neutral, increase PT MMI.N US$38.13 Neutral US$40 Buy US$31

Source: Reuters, UBS. Prices as at market close on August 15, 2011.

Markets, Events and Newsflow Today’s Company Events

Company Name Event Reuters code Rating PT Notes

Analog Devices Earnings Release ADI.N Neutral US$43

Dell Earnings Release DELL.O Buy US$18.7

Dick's Sporting Good Earnings Release DKS.N Buy US$41

Evergreen Solar Earnings Release ESLR.O Suspended #N/A

Home Depot Earnings Release HD.N Buy US$38

Perrigo Earnings Release PRGO.O Buy US$100

Photronics Inc. Earnings Release PLAB.O Buy US$11.5 Source: Reuters, UBS. Prices as at market close on August 15, 2011.


UBS 14

Today’s Macroeconomic Events: US

Indicator Time (ET) UBS forecast Previous Consensus

Weekly ICSC Store Sales (Aug 13)wow 8:45 na -0.5% na

Redbook Store Sales (Aug 13)mom 9:55 na 0.7% na

Housing Starts (Jul)lvl 9:30 na 629 k 610 k

Import Prices (Jul)mom 9:30 na -0.5% -0.1%

Industrial Production (Jul)mom 9:30 na 0.2% 0.4%

Capacity Utilization (Jul)% 9:30 na 76.7% 76.9%

Source: Bloomberg, UBS

Today’s UBS Hosted Corporate Roadshow: Company Event Location None

Today’s UBS Hosted Fieldtrip:

Company Event Location None

Today’s UBS Hosted Conference: Company Event Location

None


UBS 15

Latest Market Movements: Country/Region Market Latest Price/Last Close 1-day % Change YTD % Change

Americas

United States Dow Jones 11482.9 1.90 -0.82

United States S&P 500 1204.5 2.18 -4.23

United States Nasdaq 2555.2 1.88 -3.68

United States S&P VIX 31.87 -12.34

Europe

Europe FTSE Eurofirst300 952.6 -1.72 -15.08

Belgium BEL 20 2227.7 -2.14 -13.61

Germany DAX 5863.0 -2.64 -15.20

France CAC 3167.3 -2.22 -16.75

Italy MIB 30 15544.7 -2.16 -22.94

Netherlands AEX 287.8 -2.02 -18.84

Portugal PSI 20 6207.4 -1.95 -18.20

Spain IBEX 8554.1 -1.78 -13.24

Switzerland SMI 5256.6 -1.28 -18.33

UK FTSE 100 5274.2 -1.43 -10.61

Asia

Hong Kong Hang Seng 20188.6 -0.35 -12.36

India BSE Sensex 16902.3 0.37 -17.59

Japan Nikkei 225 9107.4 0.23 -10.96

Source: UBS, Reuters. Indices in Americas as at market close on August 15, 2011. Indices in Europe and Asia as at 05:00 EDT on August 16, 2011

Latest FX Movements: Name Currency Latest Price/Last Close 1-day % Change 1-month % Change YTD % Change

Euro €/$ 1.444 1.37% 2.1% 7.9%

UK £/$ 1.638 0.61% 1.5% 5.0%

Canada CAD/$ 1.020 0.65% -2.8% 1.8%

Switzerland CHF/$ 1.276 -0.72% 4.0% 19.2%

China Yuan/$ 0.156 -0.02% 1.1% 3.1%

Brazil BRL/$ 0.629 1.32% -1.1% 4.4%

India INR/$ 0.022 0.12% -1.8% -1.4%

Mexico MXN/$ 0.082 0.66% -4.0% 0.9%

Japan $/JPY 0.768 0.18% -2.9% -5.4%

Australia AUD/$ 1.050 1.27% -1.3% 2.6%

Source: UBS, Reuters. Prices as at market close on August 15, 2011


UBS 16

Latest Commodity Movements: Name Latest Price 1-day % Change 1-month % Change YTD % Change

Gold ($/oz) 1779.20 1.21 9.58 23.31

Brent Crude spot, $/bbl 108.83 -0.98 -8.34 15.64

WTI Crude spot, $bbl 86.70 -1.34 - -

Natural Gas, $MMBTU 3.98 -0.94 -7.13 -1.18

Source: UBS, Reuters. Prices as at market close August 16, 2011.


UBS 17

Further Information

Morning Expresso – United States Welcome to the Morning Expresso, an early morning summary of the key ideas and issues presented from UBS for the day ahead. Its contents include:

- key items from UBS’ United States Morning Meeting

- highlighted recommendation and price target changes

- today’s anticipated company, sector and macro-economic catalysts from the US Contextual Diary

- company and client events, conferences and conference calls from UBS

- overnight global market, forex and commodity movements

Morning Expresso is designed to give you all that you ‘need to know’ each morning.

Data presented is accurate as at 06:00 EDT on Tuesday, August 16, 2011.

Contacts & Feedback For further details concerning today’s Morning Expresso – United States note, please visit www.ubs.com/investmentresearch or speak to your UBS contact. This note is not intended to be static and it will evolve over time. Feedback welcomed on email to

[email protected]

Statement of Risk

Forecasting earnings and corporate financial behavior is difficult because it is affected by a wide range of economic, financial, accounting and regulatory trends, as well as changes in tax policy.


UBS 18

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.


UBS 19

Required Disclosures This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

UBS Investment Research: Global Equity Rating Allocations

UBS 12-Month Rating Rating Category Coverage1 IB Services2

Buy Buy 54% 39%Neutral Hold/Neutral 39% 35%Sell Sell 7% 14%UBS Short-Term Rating Rating Category Coverage3 IB Services4

Buy Buy less than 1% 33%Sell Sell less than 1% 25%

1:Percentage of companies under coverage globally within the 12-month rating category. 2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months. 3:Percentage of companies under coverage globally within the Short-Term rating category. 4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months. Source: UBS. Rating allocations are as of 30 June 2011. UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating Definition Buy FSR is > 6% above the MRA. Neutral FSR is between -6% and 6% of the MRA. Sell FSR is > 6% below the MRA. UBS Short-Term Rating Definition

Buy Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.

Sell Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.


UBS 20

KEY DEFINITIONS Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. Short-Term Ratings reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. Equity Price Targets have an investment horizon of 12 months. EXCEPTIONS AND SPECIAL CASES UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount. Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece. Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.


UBS 21

Company Disclosures

Company Name Reuters 12-mo rating Short-term rating Price Price date Abbott Laboratories4, 6a, 6c, 7, 8a, 16 ABT.N Buy N/A US$49.91 15 Aug 2011 Acer Inc.12 2353.TW Sell N/A NT$34.50 15 Aug 2011 Adobe Systems Inc.4, 6c, 7, 13, 16 ADBE.O Buy N/A US$24.65 15 Aug 2011 AGCO Corp.13, 16 AGCO.N Buy N/A US$40.84 15 Aug 2011 Alcatel-Lucent5, 6c, 7, 8a, 16, 18f ALUA.PA Buy N/A €2.63 15 Aug 2011 Apple Inc.6c, 7, 16, 18a AAPL.O Buy N/A US$383.41 15 Aug 2011 AT&T Inc.2, 4, 5, 6a, 6c, 7, 16 T.N Neutral N/A US$28.81 15 Aug 2011 Autodesk Inc.8a, 8b, 16 ADSK.O Buy N/A US$30.09 15 Aug 2011 Baker Hughes Inc.2, 4, 5, 6a, 6b, 6c, 7, 13, 16 BHI.N Buy N/A US$64.57 15 Aug 2011

Bank of America Corp.2, 4, 5, 6a, 6b, 6c, 7, 16, 22 BAC.N Neutral N/A US$7.76 15 Aug 2011

Boeing Co.4, 5, 6a, 6b, 6c, 7, 8a, 16, 18g BA.N Neutral N/A US$62.70 15 Aug 2011 Cardinal Health, Inc.2, 4, 6a, 6c, 7, 16,

18b, 22 CAH.N Buy N/A US$41.60 15 Aug 2011

Celgene Corporation6c, 7, 16 CELG.O Buy N/A US$55.74 15 Aug 2011 Check Point Software Technologies Ltd16 CHKP.O Buy N/A US$56.73 15 Aug 2011

Citigroup Inc2, 4, 5, 6a, 6b, 6c, 7, 16, 22 C.N Buy N/A US$31.27 15 Aug 2011 Citrix Systems Inc.16, 18h CTXS.O Neutral N/A US$62.02 15 Aug 2011 CNH Global NV4, 6a, 6b, 6c, 7, 16, 20 CNH.N Buy (CBE) N/A US$32.78 15 Aug 2011 Compal Electronics Inc. 2324.TW Sell N/A NT$29.95 15 Aug 2011 CONSOL Energy, Inc.4, 5, 6a, 16 CNX.N Buy N/A US$42.37 15 Aug 2011 Danaher Corporation2, 4, 5, 6a, 16 DHR.N Buy N/A US$44.72 15 Aug 2011 Deere & Co.16, 22 DE.N Buy N/A US$76.50 15 Aug 2011 Dell Inc.2, 4, 6a, 6b, 6c, 7, 16 DELL.O Buy N/A US$15.50 15 Aug 2011 Dow Chemical5, 6a, 6b, 6c, 7, 13, 16, 22 DOW.N Buy N/A US$30.08 15 Aug 2011 Ericsson16 ERICb.ST Buy N/A SKr72.65 15 Aug 2011 Estée Lauder16 EL.N Buy N/A US$94.27 15 Aug 2011 Ford Motor Co.4, 6a, 6b, 6c, 7, 13, 14, 16,

18c F.N Buy N/A US$11.35 15 Aug 2011

Gemalto16 GTO.PA Sell N/A €30.67 15 Aug 2011 General Electric Co.4, 5, 6a, 6b, 6c, 7, 16,

18i, 22 GE.N Buy N/A US$16.39 15 Aug 2011

Google Inc.2, 4, 5, 6a, 6b, 6c, 7, 16, 18d GOOG.O Buy N/A US$557.23 15 Aug 2011 HiSoft Technology International Ltd2, 4, 16 HSFT.O Buy N/A US$11.52 15 Aug 2011

HTC Corporation 2498.TW Buy N/A NT$827.00 15 Aug 2011 Intuit Inc.16 INTU.O Buy N/A US$43.13 15 Aug 2011 Johnson & Johnson16, 18j JNJ.N Buy N/A US$64.59 15 Aug 2011 Joy Global Inc.3, 4, 6a, 13, 16, 20 JOYG.O Buy (CBE) N/A US$81.98 15 Aug 2011 Lenovo Group Ltd16 0992.HK Buy N/A HK$4.86 15 Aug 2011 LG Electronics16 066570.KS Neutral N/A Won64,800 12 Aug 2011 Lowe's Companies, Inc.16 LOW.N Buy N/A US$19.68 15 Aug 2011 McDonalds Corp.6b, 7, 13, 16, 22 MCD.N Buy N/A US$86.82 15 Aug 2011 MediaTek Inc. 2454.TW Neutral N/A NT$266.50 15 Aug 2011 Merck & Co.4, 5, 6a, 6b, 6c, 7, 16 MRK.N Buy N/A US$32.13 15 Aug 2011 Microsoft Corp.4, 5, 6a, 6b, 6c, 7, 16, 18k, 22 MSFT.O Buy N/A US$25.51 15 Aug 2011 Motorola Mobility Holding Inc13, 16,

19 MMI.N Neutral (CBE) N/A US$38.13 15 Aug 2011

Nokia4, 5, 6a, 6b, 6c, 7, 13, 16 NOK1V.HE Neutral N/A €4.09 15 Aug 2011 Oracle Corporation16, 18l ORCL.O Buy N/A US$27.64 15 Aug 2011 Pfizer Inc.6b, 6c, 7, 16, 22 PFE.N Buy N/A US$18.34 15 Aug 2011 Prudential Financial Inc.2, 4, 6a, 6b, 6c,

7, 16, 22 PRU.N Buy N/A US$52.50 15 Aug 2011


UBS 22

Company Name Reuters 12-mo rating Short-term rating Price Price date Qualcomm Inc.16, 18e QCOM.O Buy N/A US$51.26 15 Aug 2011 Samsung Electronics16, 22 005930.KS Buy N/A Won707,000 12 Aug 2011 SanDisk Corp.13, 16, 20 SNDK.O Buy (CBE) N/A US$38.20 15 Aug 2011 Silitech Technology 3311.TW Neutral N/A NT$80.70 15 Aug 2011 Spirent Plc4, 5, 14, 16 SPT.L Buy N/A 133p 15 Aug 2011 Transocean Ltd.2, 4, 5, 6a, 6c, 7, 13, 16, 18m, 22 RIG.N Buy N/A US$57.26 15 Aug 2011

Source: UBS. All prices as of local market close. Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date 2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of

this company/entity or one of its affiliates within the past 12 months. 3. UBS Securities LLC is acting as advisor to Joy Global Inc on the announced acquisition of a stake in International Mining

Machinery. 4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking

services from this company/entity. 5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services

from this company/entity within the next three months. 6a. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking

services are being, or have been, provided. 6b. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-investment

banking securities-related services are being, or have been, provided. 6c. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-securities

services are being, or have been, provided. 7. Within the past 12 months, UBS Securities LLC has received compensation for products and services other than

investment banking services from this company/entity. 8a. The equity analyst covering this company, a member of his or her team, or one of their household members has a long

common stock position in this company. 8b. The equity analyst covering this company, a member of his or her team, or one of their household members has a long

options position in this company. 12. Directors or employees of UBS AG, its affiliates or subsidiaries are directors of this company. 13. UBS AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company`s common equity

securities as of last month`s end (or the prior month`s end if this report is dated less than 10 days after the most recent month`s end).

14. UBS Limited acts as broker to this company. 16. UBS Securities LLC makes a market in the securities and/or ADRs of this company. 18a. A U.S. based global equity strategist, a member of his team, or one of their household members has a long common

stock position in Apple, Inc. 18b. A U.S. based global equity strategist, a member of his team, or one of their household members has a long common

stock position in Cardinal Health, Inc. 18c. A U.S. based global equity strategist, a member of his team, or one of their household members has a long common

stock position in Ford Motor, Co. 18d. A U.S. based global equity strategist, a member of his team, or one of their household members has a long common

stock position in Google, Inc. 18e. A U.S. based global equity strategist, a member of his team, or one of their household members has a long common

stock position in Qualcomm Inc. 18f. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position

in Alcatel-Lucent. 18g. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position

in Boeing Co. 18h. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position

in Citrix Systems Inc.


UBS 23

18i. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in General Electric.

18j. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Johnson & Johnson.

18k. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Microsoft Corp.

18l. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Oracle Corporation.

18m. The U.S. equity strategist, a member of his team, or one of their household members has a long common stock position in Transocean Inc.

19. Because this company is an announced takeout candidate, UBS believes the security presents lower-than-normal risk. We have widened its rating band to +6%/-10% compared with +6%/-6%, respectively, under the normal rating system.

20. Because UBS believes this security presents significantly higher-than-normal risk, its rating is deemed Buy if the FSR exceeds the MRA by 10% (compared with 6% under the normal rating system).

22. UBS AG, its affiliates or subsidiaries held other significant financial interests in this company/entity as of last month`s end (or the prior month`s end if this report is dated less than 10 working days after the most recent month`s end).

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Publishing Administration. Additional Prices: Analog Devices Inc., US$32.08 (15 Aug 2011); Dick's Sporting Goods, Inc., US$32.92 (15 Aug 2011); Evergreen Solar Inc., US$0.18 (15 Aug 2011); Home Depot Inc., US$31.47 (15 Aug 2011); International Rectifier Corp., US$23.62 (15 Aug 2011); iSoftStone Holdings Ltd, US$11.46 (15 Aug 2011); NetApp Inc, US$44.31 (15 Aug 2011); Perrigo, US$88.38 (15 Aug 2011); PetSmart, Inc., US$41.86 (15 Aug 2011); Photronics Inc., US$6.19 (15 Aug 2011); Staples Inc., US$13.70 (15 Aug 2011); Source: UBS. All prices as of local market close.


UBS 24

Global Disclaimer This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. In certain countries, UBS AG is referred to as UBS SA. This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient’s individual circumstances or otherwise constitutes a personal recommendation. It is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors any investment profits nor accept any liability for any investment losses. Investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. UBS is under no obligation to update or keep current the information contained herein. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this research report. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any other source, may yield substantially different results. United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, retail clients. UBS Limited is authorised and regulated by the Financial Services Authority (FSA). UBS research complies with all the FSA requirements and laws concerning disclosures and these are indicated on the research where applicable. France: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France SA. UBS Securities France S.A. is regulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this report, the report is also deemed to have been prepared by UBS Securities France S.A. Germany: Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin). Spain: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). Turkey: Prepared by UBS Menkul Degerler AS on behalf of and distributed by UBS Limited. Russia: Prepared and distributed by UBS Securities CJSC. Switzerland: Distributed by UBS AG to persons who are institutional investors only. Italy: Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A.. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this report, the report is also deemed to have been prepared by UBS Italia Sim S.p.A.. South Africa: UBS South Africa (Pty) Limited (Registration No. 1995/011140/07) is a member of the JSE Limited, the South African Futures Exchange and the Bond Exchange of South Africa. UBS South Africa (Pty) Limited is an authorised Financial Services Provider. Details of its postal and physical address and a list of its directors are available on request or may be accessed at http:www.ubs.co.za. United States: Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate'), to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. Canada: Distributed by UBS Securities Canada Inc., a subsidiary of UBS AG and a member of the principal Canadian stock exchanges & CIPF. A statement of its financial condition and a list of its directors and senior officers will be provided upon request. Hong Kong: Distributed by UBS Securities Asia Limited. Singapore: Distributed by UBS Securities Pte. Ltd [mica (p) 039/11/2009 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte Ltd, an exempt financial advisor under the Singapore Financial Advisers Act (Cap. 110); or UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. The recipient of this report represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). Japan: Distributed by UBS Securities Japan Ltd to institutional investors only. Where this report has been prepared by UBS Securities Japan Ltd, UBS Securities Japan Ltd is the author, publisher and distributor of the report. Australia: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087) and UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098) only to 'Wholesale' clients as defined by s761G of the Corporations Act 2001. New Zealand: Distributed by UBS New Zealand Ltd. An investment adviser and investment broker disclosure statement is available on request and free of charge by writing to PO Box 45, Auckland, NZ. Dubai: The research prepared and distributed by UBS AG Dubai Branch, is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. Korea: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This report may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. Malaysia: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (253825-x).India : Prepared by UBS Securities India Private Ltd. 2/F,2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000 SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431 , NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437. The disclosures contained in research reports produced by UBS Limited shall be governed by and construed in accordance with English law. UBS specifically prohibits the redistribution of this material in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2011. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

ab